Cyclosporine A and MnTMPyP Alleviate α-Synuclein Expression and Aggregation in Cypermethrin-Induced Parkinsonism
Overview
Neurology
Authors
Affiliations
Cypermethrin induces the mitochondrial dysfunction and oxidative damage to the nigrostriatal dopaminergic neurons leading to Parkinsonism in rats. Despite α-synuclein aggregation is reported to be critical in Parkinson's disease, its role and alliance with the mitochondrial dysfunction and oxidative damage leading to cypermethrin-induced Parkinsonism have not yet been deciphered. The present study aimed to examine the effect of cypermethrin on the expression and aggregation of α-synuclein and its subsequent connection with oxidative damage and mitochondrial dysfunction leading to the nigrostriatal dopaminergic neurodegeneration in the presence or absence of a mitochondrial membrane transition pore opening inhibitor, cyclosporine A and a superoxide dismutase/catalase mimetic, manganese (III) tetrakis (1-methyl-4-pyridyl) porphyrin pentachloride (MnTMPyP). The expression of α-synuclein, 3-nitrotyrosine (3-NT), 4-hydroxynonenal (4-HNE)-modified proteins, mitochondrial dysfunction-dependent apoptotic proteins, nitrite content, lipid peroxidation (LPO) and number of tyrosine hydroxylase (TH)-positive neurons were estimated in the substantia nigra and dopamine content in the striatum of control and treated rats employing standard procedures. Cypermethrin augmented the expression of α-synuclein, 3-NT, 4-HNE-modified proteins, caspase-3, mitochondrial Bax and cytosolic cytochrome-c along with nitrite and LPO and reduced the expression of cytosolic Bax, mitochondrial cytochrome-c, dopamine and number of TH-positive neurons. Cyclosporine A or MnTMPyP alleviated the expression and aggregation of α-synuclein along with indicators of the mitochondrial dysfunction, oxidative damage and dopaminergic neurodegeneration. The results demonstrate that cypermethrin induces α-synuclein expression and aggregation while cyclosporine A or MnTMPyP rescues from α-synuclein over-expression and aggregation along with the mitochondrial dysfunction and oxidative damage leading to Parkinsonism in rats.
Singh G, Mittra N, Singh C J Mol Neurosci. 2025; 75(1):16.
PMID: 39907853 DOI: 10.1007/s12031-024-02293-5.
Imam A, Okesina A, Sulaimon F, Imam A, Ibiyeye R, Oyewole L BMC Neurosci. 2024; 25(1):45.
PMID: 39333878 PMC: 11428341. DOI: 10.1186/s12868-024-00896-7.
Sarkar A, Singh M Mol Neurobiol. 2023; 61(2):953-970.
PMID: 37674036 DOI: 10.1007/s12035-023-03591-6.
Mekircha F, Fedeli D, Nasuti C, Kecies H, Gabbianelli R, Bordoni L Antioxidants (Basel). 2023; 12(5).
PMID: 37237913 PMC: 10215152. DOI: 10.3390/antiox12051047.
Khatoon R, Kaushik P, Parvez S ACS Omega. 2022; 7(23):19106-19112.
PMID: 35721948 PMC: 9202010. DOI: 10.1021/acsomega.1c05653.